3 results
Approved WMORecruiting
• to assess the efficacy of the sequential combination strategy of front-line afatinib-chemo, followed by a treatment with osimertinib-chemo in those patients that develop a T790M mutation as a mechanism of resistance.
Approved WMOCompleted
The purpose of this study is to find out how safe and effective a new drug called bimekizumab is for long-term use in treating hidradenitis suppurativa. Bimekizumab (hereafter referred to as *the study drug*) has been approved by the health…
Approved WMOPending
The primary objective of this open-label extension (OLE) study is to assess the long-term safety and tolerability of bimekizumab administered over a period of up to 112 weeks.